This is a working overview of storage, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-07 and is reviewed periodically as new material appears.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Carbon (6C) has 14 known isotopes, from 8C to 20C as well as 22C, of which only 12C and 13C are stable. The longest-lived radioisotope is 14C, with a half-life of 5700 years. This is also the only carbon radioisotope found in nature, as trace quantities are formed cosmogenically by the reaction 14N + n → 14C + 1H. The most stable artificial radioisotope is 11C, which has a half-life of 20.34 minutes. All other radioisotopes have half-lives under 20 seconds, most less than 200 milliseconds. Lighter isotopes exhibit beta-plus decay into isotopes of boron and heavier ones beta-minus decay into isotopes of nitrogen, though at the limits particle emission occurs as well. The two lightest isotopes decay into helium via short-lived isotopes of lithium, beryllium and boron.
=== Phase 2 === AD-036 – undefined mechanism of action [6] Atomoxetine/mineralocorticoid receptor antagonist (atomoxetine/antimineralocorticoid; AD-113) – combination of atomoxetine (norepinephrine reuptake inhibitor) and a mineralocorticoid receptor antagonist [7] Atomoxetine/trazodone (trazodone/atomoxetine; AD-504) – combination of atomoxetine (norepinephrine reuptake inhibitor) and trazodone (various actions/hypnotic) [8] BAY-2586116 – potassium channel blocker [9] CX-1739 – ampakine (AMPA receptor positive allosteric modulator) [10] Dronabinol low-dose (tetrahydrocannabinol; THC; PP-001) – cannabinoid CB1 and CB2 receptor agonist [11] Dronabinol/palmidrol (SCI-110; THX-OSA01; THX-RS01; THX-110; THX-TS01; THC/PEA) – combination of dronabinol (THC; cannabinoid receptor agonist) and palmidrol (palmitoylethanolamine (PEA); various actions) [12] Lorundrostat (MLS-101; MT-4129) – aldosterone synthase (CYP11B2) inhibitor [13] Phentermine/topiramate (Qnexa; Qsiva; Qsymia; topiramate/phentermine; VI-0521) – combination of phentermine (norepinephrine releasing agent) and topiramate (various actions) [14] Research programme: Sleep disordered breathing therapeutics - Shinogi-Apnimed Sleep Science – undefined mechanisms of action [15] SASS-001 – purinergic P2X3 receptor antagonist [16] Sivopixant (S-600918) – purinergic P2X3 receptor antagonist [17] Sulthiame (SASS-002; sulthiame; Sultia; sultiame) – carbonic anhydrase inhibitor [18] [19] Trazodone/viloxazine (AD-816; viloxazine/trazodone) – combination of trazodone (various actions/hypnotic) and viloxazine (norepinephrine reuptake inhibitor) [20]
[...] The staffs concerned must have planned this for months – they had to formulate an overall operations plan, to move in the stocks necessary for the battle, to plan and to allocate the aviation resources for the deployment of troops to Georgia and other logistic capabilities, to produce a target list for the air force, and so on. [...] the scope and intensity of their attack exceeded the forecasts made by the Georgian leadership and the Western countries. The Russians achieved a strategic advantage by way of using the element of surprise." He pointed out that most of the Russian military units that fought in Georgia belonged to the North Caucasus Military District, whose capabilities surpass every other Russian districts. In June 2009, Svante Cornell wrote, "Many scholars have now shown Russia's invasion of Georgia had been long in the planning, premeditated and intended to deal a mortal blow to what Moscow saw as western encroachment in its backyard. Whatever mistakes the Georgian government may have made in being lured into war, there is little doubt Moscow provoked the conflict to bully its neighbors into submission." According to Cornell, the Kremlin spent millions in an international information campaign to blame Georgia for the war; however, there is evidence, including some in Russian media, that Russia actually started the war.
Sensitivity and specificity Accuracy and precision Repeatability Reproducibility Limit of detection – especially for trace elements Limit of quantification Curve fitting and its range System suitability – A test run each time an analysis is performed to ensure the test method is acceptable and is performing as written. This type of check is often run in a QC Lab. Usually, system suitability is performed by analyzing a standard material (House standard or reference standard) before the unknowns are run in an analytical method. Statistical analysis and other parameters must pass preset conditions to ensure the method and system are performing correctly. For example, in an HPLC purity analysis of a drug substance, a standard material of the highest purity would be run before the test samples. The parameters analyzed might be (for example) % RSD of area counts for triplicate injections or chromatographic parameters checked such as retention time. The HPLC run would be considered valid if the system suitability test passes and ensures the subsequent data collected for the unknown analytes are valid. For a longer HPLC run of over 20 samples, an additional system suitability standard (called a "check standard") might be run at the end or interspersed in the HPLC run and would be included in the statistical analysis. If all system suit standards pass, this ensures all samples yield acceptable data throughout the run, and not just at the beginning. All system suitability standards must be passed to accept the run.
Sources: en.wikipedia.org
In a survey of US laypersons in December 2021, most people believed the scientifically supported idea that trained bystanders can reverse overdoses with naloxone. A survey of US naloxone prescription programs in 2010 revealed that 21 out of 48 programs reported challenges in obtaining naloxone in the months leading up to the survey, due mainly to either cost increases that outstripped allocated funding or the suppliers' inability to fill orders. The approximate cost of a 1 ml ampoule of naloxone in the US is estimated to be significantly higher than in most other countries. Take-home naloxone programs for people who use opioids are underway in many North American cities. CDC estimates that the US programs for drug users and their caregivers prescribing take-home doses of naloxone and training on its use prevented 10,000 opioid overdose deaths by 2014. In Australia, some forms of naloxone are available "over the counter" in pharmacies free without a prescription under the Take Home Naloxone programme. It comes in single-use filled syringe form similar to law enforcement kits as well as nasal sprays. In 2024, those with a prescription can purchase five doses for around AU$32 or just over AU$6 per dose. In Alberta, in addition to pharmacy distribution, take-home naloxone kits are available and distributed in most drug treatment or rehabilitation centers. In the European Union, take home naloxone pilots were launched in the Channel Islands and in Berlin in the late 1990s.
=== Diabetes === RAGE plays a pivotal role in the pathogenesis of diabetes. RAGE, a multi-ligand receptor from the immunoglobulin superfamily, primarily binds to Advanced glycation end-products (AGEs) formed through the non-enzymatic glycation of proteins and lipids. In diabetes, hyperglycemia accelerates AGE formation, fostering a pro-inflammatory and pro-oxidative environment that worsens vascular damage and immune cell dysfunction. In both type 1 and type 2 diabetes, RAGE significantly contributes to microvascular and macrovascular complications. It is highly expressed in diabetic blood vessels, cardiomyocytes, podocytes, and immune cells, where it co-localizes with ligands such as AGEs, S100 proteins, and high-mobility group box 1 (HMGB1). This co-localization leads to chronic cellular stress and inflammation, which differs from the transient inflammatory responses associated with acute infections. RAGE activation contributes to complications such as diabetic nephropathy and retinopathy. Studies in diabetic mouse models suggest that blocking RAGE with soluble receptor forms (sRAGE) can mitigate these conditions by reducing mesangial sclerosis, basement membrane thickening, and endothelial damage. Additionally, RAGE's interaction with AGEs and S100 proteins accelerates atherosclerosis in diabetes, marked by increased lesion complexity, macrophage accumulation, and vascular inflammation.
While it is true that increased pressure, such as that exerted by someone standing on a sheet of ice, will lower the melting point of ice, experiments show that the effect is too weak to account for the lowered friction. Materials scientists still debate whether premelting or the heat of friction is the dominant cause of ice's slipperiness.
The Leaning Tower of Pizza was a proposed 30-story slanted skyscraper that would have housed Domino's Pizza's operations at its Domino's Farms campus near Ann Arbor, Michigan. In the mid-1980s, Monaghan asked Taliesin Associated Architects, the inheritors of Frank Lloyd Wright's practice, to erect a structure based on an un-built tower that Wright designed in 1956 for Chicago called the Golden Beacon. Sometime during the planning of the tower, Monaghan and the Taliesin architects parted company, allegedly because both parties felt the project may have not served justice to the spirit of Wright's architecture. Monaghan then went to Gunnar Birkerts, the architect of Domino's unusual half-mile (800 m) long headquarters office building who came up with a design for a tower that would rise at a 15-degree angle with a swooping top reminiscent of the forms of Wright's late work. Birkerts' design, no doubt, had serious intent, but would immediately and forever be dubbed with the nickname "The Leaning Tower of Pizza" after Italy's Leaning Tower of Pisa. The structure was never built but a 50-foot (15 m) tall scale model stands at the proposed site on Domino Pizza headquarters in Ann Arbor Charter Township, Michigan, outside of Ann Arbor.
===== MHCII presentation ===== In MHCII presentation, HSPs are involved in clathrin-dependent endocytosis. Also when HSPs are extracellular, they can guide their associated peptides into MHCII pathway, although it is not known how they are distinguished from the cross-presented ones (see below).
Sources: en.wikipedia.org
Gliotoxin is a sulfur-containing mycotoxin that belongs to a class of naturally occurring 2,5-diketopiperazines produced by several species of fungi, especially those of marine origin. It is the most prominent member of the epipolythiopiperazines, a large class of natural products featuring a diketopiperazine with di- or polysulfide linkage. These highly bioactive compounds have been the subject of numerous studies aimed at new therapeutics. Gliotoxin was originally isolated from Gliocladium fimbriatum, and was named accordingly. It is an epipolythiodioxopiperazine metabolite that is one of the most abundantly produced metabolites in human invasive Aspergillosis (IA).
== Nomenclature == Pyridine is a trivial name, but it has been adopted into the systematic nomenclature of derived compounds. Pyridine can occur as a substituent when another moiety of a complex compound constitutes the parent system. In such cases, the substituent is designated as pyridyl and preceded by a number indicating the atom through which the pyridine ring is bonded, for example 3-pyridyl. Pyridine rings fused to benzene are generally not referred to as pyridines; instead, systematic trivial names are used. The benzopyridines are referred to as quinolines or isoquinolines, depending on the ring arrangement.
where : x, y, and z are the stoichiometric coefficients of each species. M stands for metal / metal ion, the L for Lewis bases, and finally Z for complex ions. Formation constants vary widely. Large values indicate that the metal has high affinity for the ligand, provided the system is at equilibrium. Sometimes the stability constant will be in a different form known as the constant of destability. This constant is expressed as the inverse of the constant of formation and is denoted as Kd = 1/Kf . This constant represents the reverse reaction for the decomposition of a complex ion into its individual metal and ligand components. When comparing the values for Kd, the larger the value, the more unstable the complex ion is. As a result of these complex ions forming in solutions they also can play a key role in solubility of other compounds. When a complex ion is formed it can alter the concentrations of its components in the solution. For example:
== Research == It is under development by Cara Therapeutics as an intravenous agent for the treatment of postoperative pain. An oral formulation has also been developed. Due to its peripheral selectivity, difelikefalin lacks the central side effects like sedation, dysphoria, and hallucinations of previous KOR-acting analgesics such as pentazocine and phenazocine. In addition to use as an analgesic, difelikefalin is also being investigated for the treatment of pruritus (itching). Difelikefalin has completed phase II clinical trials for postoperative pain and has demonstrated significant and "robust" clinical efficacy, along with being safe and well tolerated. It has also completed a phase III clinical trial for uremic pruritus in hemodialysis patients.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.